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Suppression of cell migration 
by phospholipase C-related 
catalytically inactive protein-
dependent modulation of PI3K 
signalling
Satoshi Asano1, Yuri Taniguchi1, Yosuke Yamawaki1, Jing Gao2, Kae Harada  1, Hiroshi 
Takeuchi3, Masato Hirata2,4 & Takashi Kanematsu1
The metabolic processes of phosphatidylinositol 4,5-bisphosphate [PI(4,5)P2] into PI(3,4,5)P3 and 
the subsequent PI(3,4,5)P3 signalling are involved in cell migration. Dysfunctions in the control of this 
pathway can cause human cancer cell migration and metastatic growth. Here we investigated whether 
phospholipase C-related catalytically inactive protein (PRIP), a PI(4,5)P2-binding protein, regulates 
cancer cell migration. PRIP overexpression in MCF-7 and BT-549 human breast cancer cells inhibited cell 
migration in vitro and metastasis development in vivo. Overexpression of the PRIP pleckstrin homology 
domain, a PI(4,5)P2 binding motif, in MCF-7 cells caused significant suppression of cell migration. 
Consistent with these results, in comparison with wild-type cells, Prip-deficient mouse embryonic 
fibroblasts exhibited increased cell migration, and this was significantly attenuated upon transfection 
with a siRNA targeting p110α, a catalytic subunit of class I phosphoinositide 3-kinases (PI3Ks). 
PI(3,4,5)P3 production was decreased in Prip-overexpressing MCF-7 and BT-549 cells. PI3K binding to 
PI(4,5)P2 was significantly inhibited by recombinant PRIP in vitro, and thus the activity of PI3K was 
downregulated. Collectively, PRIP regulates the production of PI(3,4,5)P3 from PI(4,5)P2 by PI3K, and 
the suppressor activity of PRIP in PI(4,5)P2 metabolism regulates the tumour migration, suggesting 
PRIP as a promising target for protection against metastatic progression.
The cellular phosphoinositide metabolism pathway and its metabolite signalling are critically important for 
numerous cellular processes. Phosphatidylinositol 4,5-bisphosphate [PI(4,5)P2] constitutes about only 1% of total 
plasma membrane lipids, but is an important lipid as a membrane-bound anchoring molecule and the precursor 
of three second messengers: inositol 1,4,5-trisphosphate [Ins(1,4,5)P3], diacylglycerol and phosphatidylinositol 
3,4,5-trisphosphate [PI(3,4,5)P3]. These phospholipids and the metabolites are major signalling messengers of 
basic cellular processes, such as cell differentiation, proliferation, mitosis, migration, and cell survival. In addi-
tion, several studies have shown that dysfunctions in the control of PI(4,5)P2/PI(3,4,5)P3 signalling can often 
cause cancer1.
PI(4,5)P2 is converted to PI(3,4,5)P3 by the class I subclass of phosphatidylinositol 3-kinases (PI3Ks) that 
are activated by extracellular stimuli, including platelet-derived growth factor (PDGF) and epidermal growth 
factor. Gain-of-function mutations in PI3K [i.e., mutations in the p110 catalytic subunit of PI3K (PIK3CA)] 
thus enhance the PI(3,4,5)P3 signalling pathway and are frequently found in breast cancers and other cancers2, 3. 
The phosphatase and tensin homologue (PTEN) phosphatase enzyme dephosphorylates PI(3,4,5)P3 and termi-
nates PI3K-PI(3,4,5)P3-mediated signalling. Accordingly, loss-of-function mutations in the PTEN gene are also 
1Department of Cellular and Molecular Pharmacology, Division of Basic Life Sciences, Institute of Biomedical 
and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8553, Japan. 2Laboratory 
of Molecular and Cellular Biochemistry, Faculty of Dental Science, Kyushu University, Fukuoka, 812-8582, Japan. 
3Division of Applied Pharmacology, Kyushu Dental University, Kitakyushu, 803-8580, Japan. 4Fukuoka Dental 
College, Fukuoka, 814-0193, Japan. Correspondence and requests for materials should be addressed to T.K. (email: 
tkanema2@hiroshima-u.ac.jp)
Received: 4 April 2017
Accepted: 5 June 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 7: 5408  | DOI:10.1038/s41598-017-05908-7
frequent in human cancers1. These activated PI(3,4,5)P3 pathways induce cancer cell growth and motility, result-
ing in enhanced cancer cell migration and invasion1, 4.
Orchestrated cell motility is oriented by polarised intracellular signalling, which forms protrusive structures, such as 
lamellipodia and filopodia, at the leading edge of cells5. This process is regulated by PI(3,4,5)P3 signalling in controlling 
the actin cytoskeleton in mammalian cells. PI3K-mediated production of PI(3,4,5)P3 promotes the translocation of 
WASP family verprolin homologues protein 2 (WAVE2) to the plasma membrane and regulates guanine nucleotide 
exchange factor Rac-mediated actin filament remodelling6. WAVE2, a nucleation-promoting factor, modulates actin 
filament nucleation by bringing together actin monomers and pre-existing actin filaments at sites of active cytoskeletal 
assembly. PI(3,4,5)P3 directly binds WAVE2, which mediates membrane phosphoinositide signalling7. WAVE2 drives 
lamellipodium formation by enhancing actin nucleation via the actin-related protein 2 and 3 (ARP2/3) complex8. 
Higher levels and coexpression of WAVE2 and ARP2 were found in human metastatic lung adenocarcinoma and breast 
carcinoma, and were closely associated with poorer patient outcome9, 10.
Phospholipase C (PLC)-related catalytically inactive protein (PRIP) was originally isolated as a cytosol protein 
that binds with Ins(1,4,5)P3 through its pleckstrin homology (PH) domain11, 12. PRIP also binds to PI(4,5)P2 via its 
PH domain and localises to the plasma membrane13–15. We previously reported that Ins(1,4,5)P3 is stabilised from 
enzymatic metabolism by binding with PRIP in the cytosol, and thus PRIP regulates Ins(1,4,5)P3-Ca2+ signalling 
by Ins(1,4,5)P3 receptors13, 16. PRIP exhibits high homology to PLCδ1, but lacks PLC activity12, 17, 18. There are 
two isoforms of PRIP in mammals: PRIP1 is expressed mainly in the brain and lung, and PRIP2 is ubiquitously 
expressed19, 20. Several studies have demonstrated that PRIP regulates the intracellular trafficking machinery and 
fat metabolism21–27. However, the functions of PRIP in the regulation of phosphoinositide signalling have not 
been determined.
The PI(4,5)P2-binding but enzymatically inactive protein PRIP may regulate PI(4,5)P2/PI(3,4,5)P3 signalling. 
Thus, in this study, we examined the potential role and mechanisms of PRIP in controlling phosphoinositide 
metabolism and migration activity of cancer cells.
Results
PRIP1 inhibits the motility of MCF-7 and BT-549 breast cancer cells. To first investigate whether 
PRIP expression affects cancer cell motility, we examined the cell migration of MCF-7 cells, a human breast 
cancer cell line. MCF-7 cells contain a heterozygous E545K mutation in exon 9 of p110α of PI3K, which abro-
gates the interaction between p85 and p110 subunits, resulting in constitutive activation of the PI3K pathway 
in MCF-7 cells28–30. PRIP2, but not PRIP1, was detected in MCF-7 cells by reverse transcriptase-PCR analysis 
(Supplementary Fig. S1a). Cell migration assays showed that MCF-7 cells transiently transfected with EGFP-
Prip1 moved shorter distances than cells transfected with the empty EGFP vector (Fig. 1a). We next generated 
MCF-7 cells stably expressing EGFP-Prip1 and performed chemokinesis assays. Consistent with the results shown 
in Fig. 1a, the migration speed and D/T ratio (an index of the directness of cell trajectories; see Supplementary 
Fig. S2a) were lower in EGFP-Prip1-expressing MCF-7 cells than in EGFP vector-expressing cells (Fig. 1b).
The breast cancer cell line BT-549 lacks PTEN, a PI(3,4,5)P3 phosphatase, and thus shows excessive PI(3,4,5)P3 
accumulation at the plasma membrane31. BT-549 cells expressed both PRIP1 and PRIP2 mRNAs (Supplementary 
Fig. S1b). To examine the effect of PRIP expression on cell migration of BT-549 cells, we generated BT-549 cells 
stably overexpressing DsRed2-Prip1 or DsRed2-empty vector. Chemokinesis assay results showed that PRIP1 
expression inhibited the migration speed by approximately one-third and reduced the D/T ratio compared to 
control cells (Fig. 1c). Together these data suggest that PRIP may regulate PI3K-PI(3,4,5)P3-induced cancer cell 
migration.
PRIP inhibits the metastatic ability of BT-549 cells in vivo. Malignant tumours that are aggressive 
can invade and damage surrounding tissues. The spread of cancer cells frequently includes the invasion of local 
lymph nodes through the lymphatic system, and aggressive tumour cells typically enter the bloodstream and 
reach distant tissues32. To confirm the importance of PRIP expression in breast cancer metastasis in vivo, BT-549 
cells stably expressing DsRed2-Prip1 or vector were injected into the mammary fat pad of BALBc nude mice. At 7 
weeks after the injection, empty vector-transfected BT-549 cells spread and were localised to the regional lymph 
nodes (Fig. 1d). However, mice injected with DsRed2-Prip1-expressing BT-549 cells displayed little lymphatic 
metastasis at 7 weeks, suggesting that PRIP1 expression suppresses the metastasis of BT-549 cells.
PRIP is involved in PDGF-induced cell migration via PI3K. To investigate PRIP roles in cell move-
ment, we performed chemokinesis and chemotaxis assays in wild-type and Prip1 and Prip2 double-knockout 
(Prip-DKO) mouse embryonic fibroblasts (MEFs) using PDGF-BB, a strong cell migration inducer. Chemokinesis 
assays showed that Prip-DKO MEFs displayed increased random migration activity compared with wild-type 
MEFs (Fig. 2a). In the chemotaxis assay, cell mobility of Prip-DKO MEFs was increased and the mean forward 
migration index in Prip-DKO MEFs was about 2-fold higher than that of wild-type MEFs (Supplementary 
Fig. S2b,c). These data suggested that PRIP deficiency enhances cell mobility and directionality.
Cell migration is regulated by PI3K signalling2. We thus next examined whether PRIP is involved in 
PI3K-PI(3,4,5)P3-induced cell migration by performing chemokinesis assays in MEFs inactivated for PI3K sig-
nalling. We transfected wild-type and Prip-DKO MEFs with synthetic siRNAs targeting p110α, the class I PI3K 
catalytic subunit (mouse Pik3ca-siRNA; p110α si1 and si2). Western blot analysis confirmed that p110α pro-
tein expression was efficiently reduced to around 30% in the siRNA-transfected MEFs compared with the MEFs 
transfected with control siRNA (Supplementary Fig. S3a). AKT (also known as protein kinase B) is an immediate 
downstream mediator of PI3K. Western blot analysis confirmed inhibition of Thr308 phosphorylation of AKT in 
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Pik3ca-siRNA-transfected cells treated with PDGF stimulation, suggesting that PI3K signalling was successfully 
downregulated by Pik3ca-siRNA transfection.
In the PDGF-induced chemokinesis assays performed in control siRNA-transfected MEFs, the average migra-
tion speed and D/T ratio were 2-fold higher and 1.5-fold greater in Prip-DKO MEFs than in wild-type MEFs, 
respectively (control si, Fig. 2b). Pik3ca siRNA transfection inhibited the PDGF-induced changes in the migra-
tion speed and D/T ratio in both wild-type and Prip-DKO MEFs. Importantly, the reduced levels in Prip-DKO 
MEFs were similar to those of wild-type MEFs (Fig. 2b). Together these data suggest that PRIP is involved in 
PDGF-induced PI3K-mediated cell migration.
Cell migration is suppressed by the expression of PH domain-containing PRIP1. To identify 
the functional domain of PRIP involved in the regulation of cell migration, EGFP-tagged Prip1 or EGFP-tagged 
Prip1 truncation mutants (Fig. 3a) were transfected into MCF-7 cells and migration assays were performed. 
Transfection of full-length Prip1 or the Prip1 PHL N-terminal truncation mutant, which contains the PH domain, 
resulted in a significantly reduced migration speed and D/T ratio compared with MCF-7 cells transfected with 
the EGFP-empty vector. Importantly, the PRIP1 R134Q mutant, which does not bind PI(4,5)P233, failed to inhibit 
migration speed and D/T ratio compared with the empty control (Fig. 3b).
We then performed a scratch wound closure assay to investigate the effect of PRIP1 on lamellipodium exten-
sion at the leading edge of migrating cells and analysed lamella dynamics at the leading edge by kymography. 
Figure 1. Effect of PRIP expression on cancer cell migration and metastasis. (a) Motility of MCF-7 cells 
transiently expressing either empty vector (empty) or EGFP-tagged Prip1 (PRIP1) was monitored by 
microscopy after stimulation with medium containing 10% FBS. Representative track plots of cells are 
shown. Similar data were obtained from three independent experiments. (b,c) Random migration assays 
were performed using MCF-7 cells (b) and BT-549 cells (c) that stably expressed EGFP-tagged Prip1 or 
DsRed2-tagged Prip1, respectively. Cell migration was monitored by microscopy after stimulation with 10% 
FBS-containing medium. Cells expressing the corresponding empty vector were used as controls. Bar graphs 
show comparisons of migration speed and D/T ratio (see Supplementary Fig. S2a). Chemokinesis assays were 
performed at least three times for each indicated experiment. Data are presented as means ± SEM. The number 
of samples in empty and PRIP analyses is n = 73 and 122 (b), and n = 100 and 241 (c), respectively. **p < 0.01, 
***p < 0.001 versus empty vector (Mann–Whitney U test). (d) Female BALB/c-nu mice (n = 3 per group) were 
injected with BT-549 cells stably expressing either the empty vector or DsRed2-tagged Prip1 (5 × 106 cells/
injection) into subcutaneous tissue in the vicinity of the inguinal mammary fat pad. The panels show fluorescent 
images of DsRed2-expressing BT-549 cells in vivo at weeks 1, 5, and 7. The small panels on the far right show 
images of lymph nodes isolated from the mice at 7 weeks post-injection (areas within the squares).
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Dynamic lamellipodia were extended in MCF-7 cells expressing EGFP alone or the PRIP1 R134Q mutant, but 
were obviously inhibited in cells expressing full-length PRIP1 or PRIP1 PHL (Fig. 3c). Importantly, EGFP signals 
in cells expressing PRIP1 and PRIP1 PHL, but not PRIP1 R134Q, were detected at the edge of migrating cancer 
cells, suggesting PRIP1 containing the PH domain functions at the leading edge.
PDGF stimulation-induced lamellipodia formation also extended further in Prip-DKO MEFs than in 
wild-type MEFs in a scratch wound closure assay (Fig. 3d). Transfection of Prip1 PHL or PRIP2 PHL into 
Prip-DKO MEFs decreased the migration speed and D/T ratio compared with cells transfected with EGFP empty 
vector (Supplementary Fig. S4a). However, transfection of Prip1 ΔPH (PRIP1 lacking the N-terminal and PH 
domain) or Prip1 R134Q failed to decrease migration speed or D/T ratio. Activated PI3K induces membrane 
ruffling34; therefore, a cell spreading assay was performed to examine the involvement of PRIP in PI3K signalling. 
The area of membrane ruffling in PDGF-induced cell extension was increased in Prip-DKO MEFs compared with 
wild-type MEFs during 60 min after stimulation (Fig. 4a). The enhanced membrane ruffles in Prip-DKO MEFs 
were attenuated by transfection with Prip1 (Fig. 4b).
Figure 2. PRIP participates in PI3K-mediated cell migration. (a,b) Chemokinesis assay. Random migration 
of MEFs was monitored by microscopy after stimulation with 20 ng/mL PDGF (a). Representative track plots 
from at least three independent experiments are shown. Mouse Pik3ca-siRNAs (p110 si1 and p110 si2) and 
control siRNA (control si) were used for the experiments (b). Bar graphs show comparisons of migration speed 
and D/T ratio. Chemokinesis assays were performed at least three times for each indicated experiment. Data 
are presented as means ± SEM. The number of samples of control si, p110 si1, and p110 si2 is n = 25, 25, and 25 
in wild-type, and n = 25, 23, and 21 in Prip-DKO, respectively. *p < 0.05, **p < 0.01, ***p < 0.001 between the 
indicated bars (Kruskal–Wallis test followed by Dunn’s multiple comparison test).
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Figure 3. Pleckstrin homology domain of PRIP participates in the downregulation of cell migration and 
lamellipodium extension. (a) A schematic diagram of the constructs of PRIP1 mutants (upper panels) and 
PRIP2 mutant (lower panels). PRIP consists of a pleckstrin homology (PH) domain, X and Y domains, and C2 
domain. The numbers indicate the number of amino acid (aa) residues. (b) The migration speeds or D/T ratios 
of MCF-7 cells transfected with the indicated EGFP-tagged PRIP mutants are shown. The data were obtained 
from three independent experiments, and are presented as means ± SEM (n = 73, 140, 104, and 79 in the left-to-
right direction on each graph). *p < 0.05 versus empty vector (Kruskal–Wallis test followed by Dunn’s multiple 
comparison test). (c,d) PRIP regulates lamellipodium extension at the leading edge of migrating cells. The 
extension of the leading edge (arrowheads in the lower panels) on MCF-7 cells (c), which stably expressed either 
the empty vector or indicated EGFP-tagged constructs, and wild-type and Prip-DKO MEFs (d) was monitored 
during wound healing. The images were acquired at 1-min intervals for 60 min. The kymographs (lower panels) 
were analysed at the black lines in the upper panels. Similar results were obtained from three independent 
experiments and representative images are shown.
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To examine the localisation of PRIP, Prip-DKO MEFs were transfected with various EGFP-tagged Prip1 
mutants. Full-length PRIP1 as well as PRIP1 PHL and PRIP2 PHL accumulated at the plasma membrane in 
transfected Prip-DKO MEFs after PDGF stimulation (5 min) (Supplementary Fig. S4b). In contrast, the EGFP 
signals for PRIP1 ΔPH and PRIP1 R134Q were distributed in the cytosol, and the cells transfected with these 
plasmids displayed lamellipodia formation. Taken together, these results suggest that PRIP localises in the plasma 
membrane via the PH domain, affects PI3K activation-mediated actin remodelling, and inhibits the formation 
of lamellipodia.
Figure 4. PRIP regulates PDGF-induced cytoskeletal remodelling. (a,b) Wild-type and Prip-DKO MEFs (a) 
and Prip-DKO MEFs transfected with EGFP vector (empty) or EGFP-Prip1 (b) were grown on a fibronectin-
coated dish and starved for 3 h prior to stimulation with 20 ng/mL PDGF for the indicated period of time. 
F-actin was stained with Alexa Fluor 350 phalloidin. Arrowheads indicate ruffling membrane (a,b). Asterisks 
indicate EGFP-expressing cells (b). Similar data were obtained from at least three independent experiments, and 
representative images are shown. The graphs on the right show the membrane ruffling area relative to the total 
cell area. The data are presented as means ± SEM determined at 0, 5, 10, 30, and 60 min [(a) wild-type, n = 27, 
27, 20, 18, and 23; Prip-DKO, n = 27, 13, 23, 13, and 14; (b) empty, n = 22, 6, 12, 12, and 10; EGFP-Prip1, n = 27, 
10, 11, 11, and 14, respectively, in the left-to-right direction on the graph]. *p < 0.05, **p < 0.01, ***p < 0.001 
versus the corresponding wild-type (a) and empty vector (b) values (Mann–Whitney U test).
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PRIP regulates the biosynthesis of PI(3,4,5)P3 during lamellipodia formation. To investigate the 
involvement of PRIP in PI(3,4,5)P3 biosynthesis, we analysed phospholipid metabolism in MCF-7 and BT-549 
cells using a subcellular PI3K activity assay. The metabolism of PI(4,5)P2 to PI(3,4,5)P3 was inhibited in MCF-7 
and BT-549 cells upon overexpression of PRIP1 by approximately 75% or 65% compared with controls, respec-
tively (Fig. 5a,b). Conversely, more PI(3,4,5)P3 was detected in Prip-DKO MEFs compared with that in wild-type 
MEFs after stimulation with PDGF (Fig. 5c).
We next examined changes in PI(3,4,5)P3 and PI(4,5)P2 on the plasma membrane after PDGF stimulation 
using wild-type and Prip-DKO MEFs that overexpressed an EGFP-tagged Akt PH domain (EGFP-Akt PH), 
a probe for PI(3,4,5)P3, and an EGFP-tagged PLCδ1 PH domain (EGFP-PLCδ1 PH), a probe for PI(4,5)P235. 
Accumulation of EGFP-AKT PH signals on the plasma membrane of both wild-type and Prip-DKO MEFs 
reached a plateau at 5 min after PDGF stimulation (Fig. 5d,e). Greater accumulation of EGFP-AKT PH was 
detected in Prip-DKO MEFs than in wild-type MEFs at 5 min and 10 min post-treatment with PDGF. PDGF 
treatment of both wild-type and Prip-DKO MEFs caused a decrease of EGFP-PLCδ1 PH on the plasma mem-
brane, with a greater reduction observed in Prip-DKO MEFs compared with wild-type MEFs (Fig. 5f,g). Together 
these data suggest that PRIP is involved in regulating the production of PI(3,4,5)P3.
Acceleration of PI(3,4,5)P3-mediated downstream signalling in Prip-DKO MEFs. WAVE2 binds 
to PI(3,4,5)P3 on the plasma membrane followed by interactions with the ARP2/3 complex, which promotes actin 
polymerisation7. To investigate whether the upregulation of PI(3,4,5)P3 in Prip-DKO MEFs affects WAVE2 local-
isation to the plasma membrane, we performed immunocytochemistry with an anti-WAVE2 antibody and phal-
loidin staining to visualise F-actin (Fig. 6a). WAVE2 signals on the plasma membrane were stronger in Prip-DKO 
MEFs than wild-type MEFs without PDGF stimulation. For both genotypes, PDGF stimulation promoted the 
localisation of WAVE2 to the plasma membrane; however, the Prip-DKO MEFs displayed more apparent trans-
location of WAVE2 (right graph, Fig. 6a).
To further verify WAVE2 translocation to plasma membrane fractions, we performed centrifugal fraction-
ation analyses (Fig. 6b). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and PDGF receptor (PDGFR) 
were specifically detected in the cytosol fractions and the plasma membrane fractions, respectively, confirming 
the success of the fractionation. The expression of PDGFR was similar between wild-type and Prip-DKO MEFs 
(see whole cell lysate in Fig. 6b). In both wild-type and Prip-DKO MEFs, PDGFR was detected in plasma mem-
brane fractions and was reduced by PDGF stimulation, suggesting that PDGFR is endocytosed by PDGF stim-
ulation36. Since the phosphorylation levels of PDGFR in response to PDGF stimulation were similar in both cell 
lines, the PDGF-mediated PDGFR activation mechanism appears to be intact in both genotypes. Consistent with 
the results of the immunocytochemical assay, in basal conditions, greater accumulation of WAVE2 was observed 
in the plasma membrane fractions of Prip-DKO MEFs than wild-type MEFs (Fig. 6b). In response to PDGF 
stimulation, WAVE2 displayed further additional accumulation in the membrane fraction of Prip-DKO MEFs 
compared with that of wild-type MEFs.
We then examined the interaction between WAVE2 and ARP2 using an immunoprecipitation assay with an 
anti-WAVE2 antibody. In response to PDGF stimulation, a larger amount of ARP2 coprecipitated with WAVE2 
in Prip-DKO MEFs than in wild-type MEFs (Fig. 6c).
PRIP expression attenuates the PI(3,4,5)P3 signalling pathway. The PI3K-PI(3,4,5)P3-AKT path-
way can be activated after growth factor stimulation. Activated PI3K recruits AKT to the plasma membrane 
by binding between the AKT PH domain and PI(3,4,5)P3, which induces AKT Thr308 phosphorylation, fol-
lowed by AKT Ser473 phosphorylation by mTORC237. In MCF-7 cells, the phosphorylation levels of AKT at 
Thr308 and Ser473 were reduced in cells expressing EGFP-PRIP1 compared with control cells (Supplementary 
Fig. S3b). Prip-DKO MEFs displayed enhanced AKT phosphorylation with PDGF stimulation (Supplementary 
Fig. S3a). These data suggested that the PI3K-PI(3,4,5)P3-AKT signalling pathway is downregulated in 
PRIP1-overexpressing cells and upregulated in Prip-deficient cells. AKT activation leads to cell proliferation38. 
Indeed, PRIP deficiency in MEFs upregulated cell proliferation in culture medium supplemented with 2% or 
5% foetal bovine serum (FBS), whereas Prip1-expressing MCF-7 cells exhibited inhibited cell proliferation in 
medium with 2% or 5% FBS (Supplementary Fig. S5a,b).
PRIP suppresses the conversion of PI(4,5)P2 to PI(3,4,5)P3 by PI3K. To examine the effects of PRIP 
on the distribution of PI3Kα (p110α and p85 subunits), we performed a cell fractionation assay by centrifuga-
tion, followed by western blotting (Fig. 7a). Similar amounts of p110α and p85 subunits of PI3K were detected 
in the plasma membrane fractions after PDGF stimulation for 10 min in both wild-type and Prip-DKO MEFs. 
PDGF activates PDGFR on the cell membrane and induces complex formation between PDGFR and PI3K via 
the Src homology 2 domains of the p85 regulatory subunit, which binds to phosphorylated tyrosine on the acti-
vated PDGFR39. To investigate whether PRIP is involved in forming the complex between PDGFR and PI3K, we 
performed an immunoprecipitation assay with anti-p110α using MEF cell lysates (Fig. 7b). Similar amounts of 
PDGFR and PI3K p85 were detected in p110α immunoprecipitates, with similar PDGFR phosphorylation levels, 
in both genotypes. These data suggest that PDGF-induced PDGFR activation followed by complex formation 
between PDGFR and PI3K is not regulated by PRIP.
PRIP preferentially bound PI(4,5)P2, but not PI(3,4,5)P3 or other lipids, i.e., phosphatidylcholine (PC) and 
phosphatidylserine (Fig. 7c). We next examined if PRIP affects the interaction between PI3K and PI(4,5)P2. An 
in vitro co-sedimentation assay was performed using liposomes composed of 100% PC or 5% PI(4,5)P2 and 
95% PC (Fig. 7d). Both His-tagged p110α and p85α (PI3K complex) were precipitated with the PI(4,5)P2-PC 
liposomes (Fig. 7d), and the association was dose-dependently inhibited by PRIP1 PHL (Fig. 7e), suggesting that 
PRIP interferes with the substrate recognition of PI3K. We then investigated whether PRIP1 PHL affects PI3K 
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Figure 5. PRIP regulates the alteration of PI(3,4,5)P3 and PI(4,5)P2 on the plasma membrane. (a–c) MCF-7 
(a) and BT-549 (b) cells stably expressing EGFP-tagged Prip1 and DsRed2-tagged Prip1, respectively, and cells 
transfected with empty vectors (a,b) and wild-type and Prip-DKO MEFs (c) were used for experiments. Cells 
were incubated with BODIPY FL-PI(4,5)P2 for 1 h in medium containing 10% FBS (a,b) or 20 ng/mL PDGF 
(c). The lipids extracted from cells were distinguished by thin layer chromatography. The first lane in each 
panel (standard) shows the chromatographic mobility of 1 nmol fluorescent PI(4,5)P2. The lower panels were 
obtained using a high sensitivity mode (high). Similar data were obtained from three independent experiments, 
and representative images are shown. The PI(3,4,5)P3 bands were quantified using ImageJ software. Data are 
presented as means ± SEM [(a–c), n = 3 per group]. (d–g) MEFs transfected with either EGFP-tagged Akt PH 
(d,e) or EGFP-tagged PLCδ PH (f,g) and Kusabira-Orange-tagged actin were stimulated with 20 ng/mL PDGF 
for the indicated period of time. Similar data were obtained from at least three independent experiments, and 
representative images are shown (d,f). Fluorescence intensity of EGFP-Akt PH (e) and EGFP-PLCδ PH (g) on 
the plasma membrane was measured and normalised by the intensity of whole cells. The data are presented as 
means ± SEM determined at 0, 5, and 10 min [(e) wild-type, n = 36, 23, and 36; Prip-DKO, n = 38, 58, and 58; 
(g) wild-type, n = 41, 34, and 20; and Prip-DKO, n = 26, 49, and 19, respectively, in the left-to-right direction 
on the graph]. *p < 0.05, **p < 0.01, ***p < 0.001 versus the corresponding control value (a–c) or between the 
indicated bars (e,g) (Mann–Whitney U test).
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substrate metabolism. ELISA assays in evaluating PI3K activity towards PI(3,4,5)P3 showed reduced PI3K activity 
in response to PRIP1 PHL in a dose-dependent manner (Fig. 7f) and in response to PRIP1 (Fig. 7g), indicating 
that PRIP negatively regulates the PI3K-PI(3,4,5)P3 production pathway.
Figure 6. Alteration of PI(3,4,5)P3-mediated downstream signalling. (a–c) MEFs were stimulated with 
(+) or without (−) 20 ng/mL PDGF for 10 min. Cells were evaluated by immunocytochemistry using an 
anti-WAVE2 antibody and Alexa Fluor 350 phalloidin (a), cell fractionation assay by centrifugation (b), 
and immunoprecipitation (IP) assay using an anti-WAVE2 antibody (c). All experiments were performed 
at least three times independently, and similar data were obtained. Representative images are shown (a–c). 
The graph in (a) shows the fluorescence intensity of WAVE2 on the plasma membrane normalised by the 
intensity for the whole cell. The data are presented as means ± SEM [n = 39, 24, 34, and 24 in the left-to-right 
direction on the graph (a)]. ***p < 0.001 between the indicated bars (Kruskal–Wallis test followed by Dunn’s 
multiple comparison test). The detection of GAPDH and PDGFR in (b) represents a quality assessment of the 
purification.
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Figure 7. PRIP suppresses the conversion of PI(4,5)P2 to PI(3,4,5)P3 by PI3K. (a,b) MEFs were stimulated 
(+) with 20 ng/mL PDGF for 10 min. Treated cells were homogenised and fractionated by centrifugation (a) 
or lysed and immunoprecipitated (IP) with an anti-p110α antibody (b). Western blotting was performed with 
the indicated specific antibodies. Similar data were obtained from at least three independent experiments, 
and a set of representative images is shown. (c) Specific binding of EGFP-PRIP1 to PI(4,5)P2. Indicated lipids 
were blotted on a polyvinylidene difluoride membrane. Signals were detected using anti-PRIP1 antibody. PIP2, 
PI(4,5)P2; PIP3, PI(4,5)P3; PC, phosphatidylcholine; PS, phosphatidylserine. (d,e) A PI(4,5)P2 sedimentation 
assay was performed using recombinant His-tagged PI3Kα in the presence (+) or absence (−) of recombinant 
PRIP1 PHL (see Supplementary Fig. S6a) (d), or in the presence of the indicated dose of the PRIP1 PHL (e). 
The method is schematically presented on the left in (d). Liposomes are composed of PI(4,5)P2: PC = 5:95 
(molar ratio) (PIP2) or 100% PC (PC). The obtained lipid fractions (ppt) and supernatants (sup) were 
evaluated by western blotting using an anti-His antibody (for PI3Kα) and anti-GST antibody (for PRIP1 PHL). 
Similar data were obtained from three independent experiments, and representative images are shown. (f,g) 
Metabolic activity of PI3Kα in the production of PI(4,5)P3 in the presence of PRIP1 PHL (f) or recombinant 
PRIP1 (Supplementary Fig. S6b) (g). The data are presented as means ± SEM [(f,g) n = 3 for each indicated 
experiment]. *p < 0.05, **p < 0.01 versus the control without PRIP1 PHL (f) or PRIP1 (g) [Kruskal–Wallis test 
followed by Dunn’s multiple comparison test (f) or Mann–Whitney U test (g)].
www.nature.com/scientificreports/
1 1Scientific RepoRts | 7: 5408  | DOI:10.1038/s41598-017-05908-7
Discussion
Metastasis remains the major driver of mortality in patients with cancer. A comprehensive understanding 
of the molecular processes governing cell migration and invasion is necessary for the development of new 
anti-metastatic therapies. In this study, we revealed a novel role of PRIP in cancer cell migration as a co-modulator 
of PI(4,5)P2 in the plasma membrane. The introduction or acceleration of PRIP gene/protein expression may 
promise applications for the reduction of patient morbidity and mortality.
The constitutive activation of the PI3K/AKT signalling cascade, which typically occurs by mutations in genes 
encoding receptor tyrosine kinases PI3K, PTEN, or AKT, is very common in cancer. Deregulation of PI3K activ-
ity (e.g., H1047R and E542K in p110α) is associated with high malignancy rates and an increased resistance 
to chemotherapeutic and radiation therapies against breast cancer2, 4. The reduced expression or ablation of 
PTEN, a PI(3,4,5)P3 phosphatase, also results in malignant transformation2, 4. The breast cancer cell lines MCF-7 
and BT-549 have a mutation in exon 9 of PIK3CA and a loss of PTEN, respectively, and display a PI(3,4,5)P3 
overproduction-linked malignant phenotype3, 31. Therefore, we used these two cell lines to investigate the involve-
ment of PRIP in PI(3,4,5)P3 signalling. Our results demonstrate that the introduction of Prip1 into MCF-7 and 
BT-549 cells inhibits cancer cell migration and membrane extension, and this action was required for PRIP bind-
ing to PI(4,5)P2 via the PH domain (Figs 1 and 3). Furthermore, the ablation of Prip from MEFs upregulated cell 
migration and membrane extension (Figs 2, 3, 4, and Supplementary Fig. S4), suggesting inhibitory effects of 
PRIP on cell migration.
PRIP1 was originally purified from rat brain cytosol11 and has since been isolated from membrane fractions14. 
A previous study showed that recombinant PRIP1 PH domain binds to Ins(1,4,5)P3 with KD = 15.6 μM and glyc-
erophosphoinositol 4,5-diphosphate with KD = 125 μM in vitro40. In this study, EGFP-tagged PRIP1 preferentially 
bound to PI(4,5)P2 rather than PI(3,4,5)P3 (Fig. 7c), and PRIP1 and PRIP1 PH localised to the leading edge of the 
plasma membrane during lamellipodia-based migration (Fig. 3c), suggesting that PRIP localises to PI(4,5)P2 and 
regulates PI(3,4,5)P3 production. Consistently, PI(3,4,5)P3 accumulation and higher production-mediated down-
stream signalling were observed in Prip-deficient cells compared with normal cells (Figs 5 and 6). In addition, 
the PI(4,5)P2 metabolism via PI3K was inhibited by the PRIP PH domain (Fig. 7). These data indicated that PRIP 
prevents the PI3K-mediated conversion of PI(4,5)P2 into PI(3,4,5)P3.
The overexpression of Prip1 in MCF-7 and BT-549 cells disrupted both the speed and directionality of 
cell migration (Fig. 1b,c, and PRIP1 lanes in Fig. 3b). These effects were mimicked by the introduction of the 
PRIP-PH domain mutant (Fig. 3b). Consistent with these results, Prip-deficient MEFs displayed accelerated cell 
migration and directionality compared with wild-type MEFs (control siRNA lanes in Fig. 2b). These enhanced 
effects were inhibited by the introduction of PRIP1 and PRIP2 PHL domain mutants, but not inhibited by the 
PRIP1 ΔPH mutant or the PRIP1 R134Q mutant, which does not bind PI(4,5)P2 (Supplementary Fig. S4). These 
data indicate that cell migration activity is primarily regulated by the PRIP PH domain via binding with PI(4,5)P2. 
Furthermore, overexpression analysis using PLCδ PH showed differences in phospholipid metabolism between 
Prip-DKO and wild-type MEFs, suggesting that PLCδ PH cannot rescue the Prip-DKO phenotype to the nor-
mal phenotype (Fig. 5f,g). In contrast, PRIP PHL rescued PRIP functions in Prip-DKO MEFs, indicating that 
phosphoinositide signalling via PRIP is specific for the PHL domain of PRIP. Interestingly, PRIP1 PHS, a short 
PH domain mutant, showed different localisation compared with the PRIP1 PHL in MEFs (Supplementary 
Fig. S4b,c). PRIP1 PHS signals displayed weak localisation on the plasma membrane; however, lamellipodia for-
mation was inhibited after PDGF stimulation. Therefore, the PRIP N-terminal region (1–74 aa) is needed to 
express the specific function of PRIP PH in phospholipid metabolism.
Migration is a polarised cellular process, and the polarity can regulate cell mobility in a specific direction41. 
Our scratch wound closure assays revealed that the expression of PRIP inhibited protrusive front edge formation, 
which was regulated by actin remodelling via PI3K-WAVE2-ARP2/3 signalling (Figs 3 and 6). Moreover, cell 
migration is regulated not only by WAVE2-ARP2/3 signalling, but also by phosphorylated AKT (activated form), 
which promotes myosin II assembly followed by actomyosin contractions by mediating p21-activated kinase 
phosphorylation42, 43. Thus, a dramatic modulation of PI(3,4,5)P3 production coordinated by PRIP1 and PRIP2 
may also regulate AKT-mediated cell motility. Further investigations are needed.
Epithelial-mesenchymal transition (EMT) is a developmental process in which epithelial cells acquire migra-
tory and invasive properties44. Mesenchymal markers are expressed in BT-549 cells but not in MCF-7 cells45. 
Our result showed that stably overexpressed PRIP in BT-549 cells suppressed the metastatic ability (Fig. 1d). 
Importantly, the overexpression partially reversed the expression pattern of EMT markers (Supplementary 
Fig. S7), suggesting PRIP is a negative regulator for EMT in breast cancer cells. However, PRIP roles in EMT 
program need further investigation.
This is the first study to examine the roles of PRIP in phospholipid metabolism and cell migration. Our find-
ings conclusively demonstrated that PRIP can regulate cancer cell migration activity in vitro and metastasis 
development in vivo. The novel tumour migration suppressor activity of PRIP was preferentially correlated with 
PI3K-PI(3,4,5)P3 production signalling. As a key regulatory mechanism, we propose that the association of PRIP 
with PI(4,5)P2 suppresses the conversion of PI(4,5)P2 into PI(3,4,5)P3 by PI3K (Fig. 8). Hence, this new mole-
cule regulating phosphoinositide metabolism is a potential therapeutic target for protection against metastatic 
progression.
Methods
Plasmids and siRNAs. EGFP-tagged PLCδ1 PH, Akt PH, Prip1 (full-length rat Prip1 gene), Prip1 PHL, 
Prip1 ΔPH, Prip1 R134Q and PRIP2 PHL (human PRIP2 PH domain gene), DsRed-Prip1 (full-length), and 
GST-tagged Prip1 PHL were described previously15, 46. Kusabira-Orange-tagged β-actin (KO1-actin) was pur-
chased from Medical & Biological Laboratories (Nagoya, Japan). Human p110α (PIK3CA)-siRNA (si1, 1116744; 
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si2, 1116747) and mouse Pik3ca-siRNA (si1, 1408655; si2, 1408665) were purchased from Bioneer Corporation 
(Daejeon, Korea). A negative control siRNA (S10C-0600) was purchased from Cosmo Bio (Tokyo, Japan).
Antibodies. Anti-ARP2 (#5614), anti-GAPDH (#2118), anti-PDGF receptor β (#3169), anti-phospho-PDGF 
receptor β (Tyr751; #4549), anti-PI3 kinase p85 (#4257), anti-PI3-kinase p110α (#4249), anti-WAVE2 (#3659), 
and HRP-conjugated anti-rabbit IgG (#7074) were purchased from Cell Signaling Technology (Beverly, MA, 
USA). Anti-PRIP1 polyclonal antibody was developed previously21. Anti-β-actin (IMG-5142A) was obtained 
from Imgenex (San Diego, CA, USA). Anti-His (D291-3S), anti-GST (M209-3), and normal rabbit IgG (PM035) 
were obtained from Medical & Biological Laboratories. HRP-conjugated anti-mouse IgG (NA9310) was obtained 
from GE Healthcare (Little Chalfont, UK). Alexa Fluor 488 anti-rabbit IgG (A-11008) was obtained from 
Invitrogen (Carlsbad, CA, USA).
Cell culture and transfection. The BT-549 cell line was purchased from the American Type Culture 
Collection (ATCC; Rockville, MD, USA). Preparation of wild-type and Prip-DKO MEFs was described previ-
ously25. MEFs were immortalised by transfecting the simian virus 40 large T antigen. Cells were cultured under 
conventional growth conditions and transfected with plasmids or siRNA using the Lonza 4D-Nucleofector X Unit 
(Lonza, Basel, Switzerland) or Lipofectamine 3000 (Invitrogen).
Production of stable PRIP-expressing cells. Cells were transfected with the expression vectors coding 
EGFP-Prip1 or DsRed2-Prip1 and cultured in the presence of 1 mg/ml G418 (Nakarai Tesque, Kyoto, Japan) for 
14 days. Stable colonies that expressed fluorescent protein were selected for further experiments.
Random migration assay and cell spreading assay. MCF-7 and BT-549 cells (1.5 × 104) were seeded 
on culture dishes or glass coverslips coated with fibronectin in serum-free medium, cultured until attached, 
and stimulated with 20 ng/mL PDGF-BB (for MEFs; Peprotech, Rocky Hill, NJ, USA) or 10% FBS (for MCF-7 
and BT-549 cells). For the migration assay, cells were monitored every 30 min for 18 h by live-cell imaging (BZ-
9000; Keyence, Osaka, Japan). Tracking analysis of cells was performed using Image-Pro premier ver.9.4 (Media 
Cybernetics, Rockville, MD, USA). For the cell spreading assay, cells were fixed, F-actin was stained with Alexa 
Fluor 350 phalloidin, and a confocal laser scanning microscope was used for observations (Fluoview FV10i; 
Olympus, Tokyo, Japan). The intensity for the cell edge and ruffling area was measured by ImageJ 1.45 s (National 
Institutes of Health, Bethesda, MD, USA). To observe the extension of the leading edge, cells were seeded on 
μ-dishes (Ibidi, Martinsried, Germany), cultured until confluent, wounded with a pipet tip, and stimulated with 
20 ng/mL PDGF-BB (for MEFs) or 10% FBS (for MCF-7 cells). The cells were recorded every 1 min for 60 min by 
live-cell imaging on a BZ-9000 microscope. Kymography analysis of the leading edge was performed using the 
MultipleKymograph plug-in of ImageJ 1.45 s (National Institutes of Health; developed by J. Rietdorf and A. Seitz).
Mouse metastasis study and ethics statement. BT-549 breast cancer metastasis was assayed by 
the modified method of Wiegmans et al.47. Briefly, five-week-old age-matched female nude mice (BALB/c-nu; 
Charles River Japan, Yokohama, Japan) were injected into the mammary fat pad with metastatic BT549 cells 
stably expressing DsRed2-Prip1 or a control empty vector (5 × 106 cells/100 μL of phosphate-buffered saline). 
Tumour growth and metastasis was visualised using NightOWL (Berthold Technologies, Bad Wildbad, Germany) 
for live animal imaging and monitored weekly. All procedures and animal work were approved by the Animal 
Care and Use Committee of Hiroshima University (permission number: A15-119) and were performed in accord-
ance with the Guide for Hiroshima University Animal Experimentation Regulation.
Figure 8. Schematic representation of PRIP-mediated cell migration. PRIP binds to PI(4,5)P2 via its PH 
domain and sequesters PI(4,5)P2 from a metabolizing enzyme PI3K. This inhibits the interaction between 
p110α, catalytic subunit of PI3K, and PI(4,5)P2. When PI3K is activated by growth factor stimulation, the 
excessive metabolism to PI(3,4,5)P3 is protected by the proper access of the PI3K to PI(4,5)P2. PRIP is a negative 
modulator for PI(3,4,5)P3-WAVE2-induced actin polymerization and cell migration. PI3K: a heterodimer 
between a p110 catalytic subunit and a p85 regulatory subunit.
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Immunofluorescence, immunoprecipitation, and western blotting. Immunofluorescence, immu-
noprecipitation, and western blotting were carried out following previously described methods24. F-actin was 
visualised by Alexa Fluor 350-labelled phalloidin (Invitrogen). Cell fractionation was performed using the 
Minute Plasmid Membrane Protein Isolation Kit (Invent Biotechnologies, Plymouth, MN, USA) according to the 
manufacturer’s protocol.
Thin-layer chromatography. For the assessment of PI(3,4,5)P3 levels in cells, cells were incubated with 
mixture of 20 μM BODIPY FL-PtdIns(4,5)P2 (C-45F6a; Echelon, San Jose, CA, USA) and carrier 2 (P-9C2, 
Echelon) for 60 min at 37 °C and washed twice with ice-cold phosphate-buffered saline. Lipids were extracted by 
CHCl3/MeOH (v/v = 2:1) using the methods of Bligh and Dyer48, applied to thin-layer chromatography plates, and 
developed in CHCl3/acetone/MeOH/AcOH/water (v/v/v/v/v = 40:15:13:12:7) using the methods of Huang et al.49. 
The fluorescent lipids were visualised using the Molecular Imager FXTM (Bio-Rad, Hercules, CA, USA).
Measurement of PI(4,5)P2 and PI(3,4,5)P3 levels at the plasma membrane. KO1-Actin and 
EGFP-PLCδ1 PH or EGFP-Akt PH were co-expressed in MEFs, and cell spreading assay was performed as 
described above. The EGFP intensities on the plasma membrane was measured and normalised by the intensity 
of whole cells.
Liposome sedimentation assay and measurement of PI3K activity. A binding assay of PI3K to 
liposomes containing with PI(4,5)P2 was carried out following previously described methods15, with modifica-
tions, using recombinant His-tagged PI3Kα (10 pg; Jena Bioscience, Jena, Germany) and PI(4,5)P2 (Cayman, 
Ann Arbor, MI, USA) and/or PC (Sigma-Aldrich, St. Louis, MO, USA) in the presence or absence of purified 
recombinant GST-tagged PRIP1 PHL. PI3K activity was measured in vitro using the PI3-Kinase Activity ELISA 
Kit (Echelon).
Statistical analysis. GraphPad Prism was used for the statistical analyses. A non-parametric Mann–
Whitney U test (for two groups) and Kruskal–Wallis test (for more than two groups) followed by Dunn’s multiple 
comparison test were used. A p-value of less than 0.05 was considered statistically significant.
Availability of materials and data. All data generated or analysed during this study are included in this 
published article and its Supplementary Information file. Other relevant information is available from the authors 
on reasonable request.
Ethics approval. All procedures and animal work were approved by the Animal Care and Use Committee 
of Hiroshima University (A15-119) and were performed in accordance with the Guide for Hiroshima University 
Animal Experimentation Regulation.
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